Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Consolidated Net Income: 2009-2024

Historic Consolidated Net Income for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to -$4.0 million.

  • Ligand Pharmaceuticals' Consolidated Net Income rose 1735.15% to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 7.38%. This contributed to the annual value of -$4.0 million for FY2024, which is 142.16% down from last year.
  • According to the latest figures from FY2024, Ligand Pharmaceuticals' Consolidated Net Income is -$4.0 million, which was down 142.16% from -$1.7 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Consolidated Net Income ranged from a high of -$1.7 million in FY2023 and a low of -$28.1 million during FY2022.
  • For the 3-year period, Ligand Pharmaceuticals' Consolidated Net Income averaged around -$11.3 million, with its median value being -$4.0 million (2024).
  • In the last 5 years, Ligand Pharmaceuticals' Consolidated Net Income surged by 94.08% in 2023 and then crashed by 142.16% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Consolidated Net Income (Yearly) stood at -$9.6 million in 2020, then tumbled by 100.51% to -$19.2 million in 2021, then tumbled by 46.46% to -$28.1 million in 2022, then skyrocketed by 94.08% to -$1.7 million in 2023, then plummeted by 142.16% to -$4.0 million in 2024.